Jardiance (Empagliflozin) Patent Expiration, LOE Window & CMS Spending

Jardiance (Empagliflozin) by Boehringer Ingelheim: FDA Orange Book core substance LOE 2029-02-01 (last listed 2034-12-11), 1 AB generics, $13.68B 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBoehringer Ingelheim
FDA Application & PathwayN204629 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2029-02-01
Last Listed Patent or Exclusivity Date2034-12-11
Orange Book Patents (*PED Extensions)27 patents (12 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$13.68B
2024 Medicare Part D Spend$11.44B
2024 Medicaid Spend$2.24B
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.